valsartan has been researched along with Cardiac Toxicity in 14 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (14.29) | 24.3611 |
| 2020's | 12 (85.71) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, L; Cheng, D; Fang, W; Liu, H; Tu, W; Wang, H; Wang, Q; Yu, Q; Zhu, N | 1 |
| Akokay, P; Dindaş, F; Doğduş, M; Ekici, M; Erhan, F; Güngör, H; Yılmaz, MB | 1 |
| Kim, BS; Kim, HJ; Lee, AH; Lim, YH; Park, IH; Shin, JH | 1 |
| Akagi, S; Amioka, N; Hatipoglu, OF; Ito, H; Miyoshi, T; Nakamura, K; Saito, Y; Yonezawa, T; Yoshida, M | 1 |
| Gok, M; Ozturk, C; Yalta, K; Yalta, T | 1 |
| Lewicka, E; Sławiński, G | 1 |
| Dogan, Z; Durmus, S; Ergun, DD; Gelisgen, R; Sahin, H; Senturk, GE; Senyigit, A; Uzun, H | 1 |
| Ahmed Rifaai, R; Bayoumi, AMA; Mahmoud Refaie, MM; Shehata, S | 1 |
| Chen, L; Cheng, D; Li, Z; Meng, L; Tu, W; Wang, H; Wang, Q; Yu, Q | 1 |
| Dankowski, R; Nowicka, A; Sacharczuk, W; Szałek-Goralewska, A; Szyszka, A; Łojko-Dankowska, A | 1 |
| Alanazi, AZ; Alanazi, WA; Alhazzani, K; Alhoshani, AR; Aljerian, K; Alotaibi, FN; Alotaibi, MR; Alswayyed, M; As Sobeai, HM | 1 |
| Asselin, CY; Cheung, D; Czaykowski, P; Dingman, B; Edel, A; Goyal, V; Jassal, DS; Kim, E; Mittal, I; Mozolevska, V; Ravandi, A; Schwartz, A; Shaikh, B; Singal, PK; Thliveris, J | 1 |
| Balmforth, C; Jhund, PS; Lefkowitz, M; McMurray, JJV; Packer, M; Rizkala, AR; Rouleau, JL; Shen, L; Shi, V; Simpson, J; Solomon, SD; Swedberg, K; Zile, MR | 1 |
| Abdeltawab Mohammed, M; Aboud, HM; Mahmoud, MO; Sabry, D; Shafiq Awad, M | 1 |
1 trial(s) available for valsartan and Cardiac Toxicity
| Article | Year |
|---|---|
Outcomes and Effect of Treatment According to Etiology in HFrEF: An Analysis of PARADIGM-HF.
Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Cardiomyopathy, Alcoholic; Cardiomyopathy, Dilated; Cardiotoxicity; Cardiovascular Diseases; Cause of Death; Dangerous Behavior; Diabetic Cardiomyopathies; Drug Combinations; Enalapril; Female; Heart Failure; Heart Valve Diseases; Hospitalization; Humans; Hypertension; Infections; Male; Middle Aged; Mortality; Myocardial Ischemia; Peripartum Period; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan; Virus Diseases | 2019 |
13 other study(ies) available for valsartan and Cardiac Toxicity
| Article | Year |
|---|---|
MSCs enhances the protective effects of valsartan on attenuating the doxorubicin-induced myocardial injury via AngII/NOX/ROS/MAPK signaling pathway.
Topics: Animals; Antibiotics, Antineoplastic; Cardiotoxicity; Cell Survival; Doxorubicin; Humans; MAP Kinase Signaling System; Mesenchymal Stem Cells; Myocytes, Cardiac; Oxidative Stress; Reactive Oxygen Species; Signal Transduction; Valsartan | 2021 |
Angiotensin receptor-neprilysin inhibition by sacubitril/valsartan attenuates doxorubicin-induced cardiotoxicity in a pretreatment mice model by interfering with oxidative stress, inflammation, and Caspase 3 apoptotic pathway.
Topics: Aminobutyrates; Angiotensins; Animals; Biphenyl Compounds; Cardiotoxicity; Caspase 3; Doxorubicin; Inflammation; Mice; Neprilysin; Oxidative Stress; Receptors, Angiotensin; Valsartan | 2021 |
Sacubitril/valsartan reduces endoplasmic reticulum stress in a rat model of doxorubicin-induced cardiotoxicity.
Topics: Aminobutyrates; Animals; Biphenyl Compounds; Cardiotoxicity; Doxorubicin; Drug Combinations; Endoplasmic Reticulum Stress; Heart Failure; Male; Rats; Rats, Sprague-Dawley; Valsartan; Water | 2022 |
LCZ696 ameliorates doxorubicin-induced cardiomyocyte toxicity in rats.
Topics: Aminobutyrates; Animals; Apoptosis; Biphenyl Compounds; Cardiotoxicity; Doxorubicin; Drug Combinations; Male; Myocytes, Cardiac; Oxidative Stress; Rats; Rats, Sprague-Dawley; Reactive Oxygen Species; Valsartan | 2022 |
Sacubitril-valsartan: Hope or hype in the battle against cardiotoxicity due to cancer treatment?
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Cardiotoxicity; Drug Combinations; Heart Failure; Humans; Neoplasms; Stroke Volume; Tetrazoles; Valsartan | 2022 |
Sacubitril-valsartan: Hope or hype in the battle against cardiotoxicity due to cancer treatment? Authors' reply.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Cardiotoxicity; Drug Combinations; Heart Failure; Humans; Neoplasms; Stroke Volume; Tetrazoles; Valsartan | 2022 |
Empagliflozin and sacubitril/valsartan reverse methotrexate cardiotoxicity by repressing oxidative stress and hypoxia in heart embryonic H9c2 cardiomyocytes - the role of morphology of mitochondria observed on electron microscopy.
Topics: Animals; Antioxidants; Cardiotoxicity; Hypoxia; Hypoxia-Inducible Factor 1, alpha Subunit; Methotrexate; Microscopy, Electron; Mitochondria; Myocytes, Cardiac; Oxidants; Oxidative Stress; Rats; Valsartan | 2023 |
Sacubitril/valsartan cardioprotective effect against cisplatin-induced cardiotoxicity via modulation of VEGF/eNOS and TLR4/TNFα/IL6 signalling pathways.
Topics: Animals; Cardiotoxicity; Cisplatin; Interleukin-6; Male; Nitric Oxide Synthase; Rats; Rats, Wistar; Toll-Like Receptor 4; Tumor Necrosis Factor-alpha; Valsartan; Vascular Endothelial Growth Factor A | 2023 |
Protective effects of valsartan administration on doxorubicin‑induced myocardial injury in rats and the role of oxidative stress and NOX2/NOX4 signaling.
Topics: Animals; Apoptosis; Cardiotoxicity; Cell Line; Disease Models, Animal; Doxorubicin; Gene Expression Regulation; Heart Function Tests; Male; NADPH Oxidase 2; NADPH Oxidase 4; Oxidative Stress; Random Allocation; Rats; Rats, Sprague-Dawley; Reactive Oxygen Species; Signal Transduction; Valsartan | 2020 |
Sacubitril/valsartan as first-line therapy in anthracycline-induced cardiotoxicity.
Topics: Aminobutyrates; Anthracyclines; Biphenyl Compounds; Cardiotoxicity; Drug Combinations; Humans; Valsartan | 2021 |
Protective effect of valsartan against doxorubicin-induced cardiotoxicity: Histopathology and metabolomics in vivo study.
Topics: Animals; Cardiotonic Agents; Cardiotoxicity; Doxorubicin; Gene Expression Regulation; Male; Metabolomics; Rats; Rats, Sprague-Dawley; Valsartan | 2021 |
Role of renin-angiotensin system antagonists in the prevention of bevacizumab- and sunitinib-mediated cardiac dysfunction.
Topics: Amides; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Antineoplastic Agents; Bevacizumab; Cardiotoxicity; Fumarates; Hydralazine; Male; Mice; Mice, Inbred C57BL; Perindopril; Renin-Angiotensin System; Sunitinib; Valsartan; Ventricular Dysfunction | 2019 |
Preparation and appraisal of self-assembled valsartan-loaded amalgamated Pluronic F127/Tween 80 polymeric micelles: Boosted cardioprotection
Topics: Animals; Cardiotonic Agents; Cardiotoxicity; Cisplatin; Drug Liberation; Male; Micelles; NF-E2-Related Factor 2; Particle Size; Poloxamer; Polymers; Polysorbates; Rats; Rats, Wistar; RNA, Long Noncoding; Thioredoxins; Valsartan | 2020 |